It can be noted that the European trials for hematological malignancies are studying new antigenic targets; for example, SLAMF7 (multiple myeloma), CD44v6 (acute myeloid leukemia and multiple myeloma), or TRBC1 (large B-cell lymphoma). Here, TRBC1 is linked to hematologic disorder.